Avadel Pharmaceuticals PLC (FRA:AWK)
€ 11.6 0 (0%) Market Cap: 1.12 Bil Enterprise Value: 1.05 Bil PE Ratio: 0 PB Ratio: 20.33 GF Score: 39/100

Avadel Pharmaceuticals PLC at Ladenburg Thalmann Virtual Healthcare Conference Transcript

Jul 14, 2021 / 03:00PM GMT
Release Date Price: €5.6 (-0.88%)
Matthew Kaplan
Ladenburg Thalmann & Co. Inc. - Analyst

Good morning. It's my pleasure to introduce our next presenting company, Avadel. Presenting for the company is Greg Divis, CEO. And Greg, we look forward to this chat -- fireside chat that we are going to have.

Questions & Answers

Matthew Kaplan
Ladenburg Thalmann & Co. Inc. - Analyst

And I want to kick it off with -- I guess for people that aren't familiar with Avadel, can you give us a little bit of a brief background on the Company and your overall vision for the Company as well?

Greg Divis
Avadel Pharmaceuticals plc - CEO

Yes, Matt. First of all, thanks for the opportunity to be here and the chance to participate in your conference. We really greatly appreciate it. Avadel is a biopharmaceutical company that is primarily focused today on the development of our investigational, once-nightly-at-bedtime FT218, which is our once-nightly formulation of sodium oxybate for patients suffering from narcolepsy and specifically patients suffering

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot